|
1
|
Arzoun H, Srinivasan M, Thangaraj SR,
Thomas SS and Mohammed L: The progression of chronic myeloid
leukemia to myeloid sarcoma: A systematic review. Cureus.
14:e210772022.PubMed/NCBI
|
|
2
|
Tsuchiya K, Tabe Y, Ai T, Ohkawa T, Usui
K, Yuri M, Misawa S, Morishita S, Takaku T, Kakimoto A, et al:
Eprobe mediated RT-qPCR for the detection of leukemia-associated
fusion genes. PLoS One. 13:e02024292018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Luatti S, Baldazzi C, Marzocchi G, Ameli
G, Bochicchio MT, Soverini S, Castagnetti F, Tiribelli M, Gugliotta
G, Martinelli G, et al: Cryptic BCR-ABL fusion gene as variant
rearrangement in chronic myeloid leukemia: Molecular cytogenetic
characterization and influence on TKIs therapy. Oncotarget.
8:29906–29913. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abdulmawjood B, Costa B, Roma-Rodrigues C,
Baptista PV and Fernandes AR: Genetic biomarkers in chronic myeloid
leukemia: What have we learned so far? Int J Mol Sci. 22:125162021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Soverini S, Mancini M, Bavaro L, Cavo M
and Martinelli G: Chronic myeloid leukemia: The paradigm of
targeting oncogenic tyrosine kinase signaling and counteracting
resistance for successful cancer therapy. Mol Cancer. 17:492018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Abdullah MA, Amer A, Nawaz Z, Abdullah AS,
Al-Sabbagh A, Kohla S, Nashwan AJ and Yassin MA: An uncommon case
of chronic myeloid leukemia with variant cytogenetic. Acta Biomed.
89:28–32. 2018.PubMed/NCBI
|
|
7
|
Al-Bayati AMS, Al-Bayti AAH and Husain VI:
A short review about chronic myeloid leukemia. J Life Bio Sci Res.
4:15–19. 2023. View Article : Google Scholar
|
|
8
|
Iqbal Z, Absar M, Akhtar T, Aleem A,
Jameel A, Basit S, Ullah A, Afzal S, Ramzan K, Rasool M, et al:
Integrated genomic analysis identifies ANKRD36 gene as a novel and
common biomarker of disease progression in chronic myeloid
leukemia. Biology (Basel). 10:11822021.PubMed/NCBI
|
|
9
|
Burmeister T and Reinhardt R: A multiplex
PCR for improved detection of typical and atypical BCR-ABL fusion
transcripts. Leuk Res. 32:579–585. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xue M, Wang Q, Huo L, Wen L, Yang X, Wu Q,
Pan J, Cen J, Ruan C, Wu D and Chen S: Clinical characteristics and
prognostic significance of chronic myeloid leukemia with rare
BCR-ABL1 transcripts. Leuk Lymphoma. 60:3051–3057. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Molica M, Abruzzese E and Breccia M:
Prognostic significance of transcript-Type BCR-ABL1 in chronic
myeloid leukemia. Mediterr J Hematol Infect Dis. 12:e20200622020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schäfer V, White HE, Gerrard G, Möbius S,
Saussele S, Franke GN, Mahon FX, Talmaci R, Colomer D, Soverini S,
et al: Assessment of individual molecular response in chronic
myeloid leukemia patients with atypical BCR-ABL1 fusion
transcripts: Recommendations by the EUTOS cooperative network. J
Cancer Res Clin Oncol. 147:3081–3089. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jean J, Sukhanova M, Dittmann D, Gao J and
Jennings LJ: A novel BCR::ABL1 variant detected with multiple
testing modalities. Case Rep Hematol. 2024:84862672024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Crampe M, Kearney L, O'Brien D, Bacon CL,
O'Shea D and Langabeer SE: Molecular monitoring in adult
philadelphia chromosome-positive acute lymphoblastic leukemia with
the variant e13a3 BCR-ABL1 fusion. Case Rep Hematol.
2019:96350702019.PubMed/NCBI
|
|
15
|
Hu LH, Pu LF, Yang DD, Zhang C, Wang HP,
Ding YY, Li MM, Zhai ZM and Xiong S: How to detect the rare BCR-ABL
(e14a3) transcript: A case report and literature review. Oncol
Lett. 14:5619–5623. 2017.PubMed/NCBI
|
|
16
|
Li Y, Zhang Y, Meng X, Chen S, Wang T,
Zhang L and Ma X: Chronic myeloid leukemia with two rare fusion
gene transcripts of atypical BCR::ABL: A case report and literature
review. Medicine (Baltimore). 103:e367282024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pecciarini L, Brunetto E, Grassini G, De
Pascali V, Ogliari FR, Talarico A, Marra G, Magliacane G, Redegalli
M, Arrigoni G, et al: Gene fusion detection in NSCLC routine
clinical practice: Targeted-NGS or FISH? Cells. 12:11352023.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee T, Clarke JM, Jain D, Ramalingam S and
Vashistha V: Precision treatment for metastatic non-small cell lung
cancer: A conceptual overview. Cleve Clin J Med. 88:117–127. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Su YJ, Kuo MC, Chen TY, Wang MC, Yang Y,
Ma MC, Lin TL, Lin TH, Chang H, Teng CJ, et al: Comparison of
molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2
transcripts in chronic myeloid leukemia. Cancer Sci. 113:3518–3527.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Leong WMS and Aw CWD: Nilotinib-induced
keratosis pilaris. Case Rep Dermatol. 8:91–96. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cross NCP, Ernst T, Branford S, Cayuela
JM, Deininger M, Fabarius A, Kim DDH, Machova Polakova K, Radich
JP, Hehlmann R, et al: European LeukemiaNet laboratory
recommendations for the diagnosis and management of chronic myeloid
leukemia. Leukemia. 37:2150–2167. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kearney L, Crampe M and Langabeer SE:
Frequency and spectrum of atypical BCR-ABL1 transcripts in chronic
myeloid leukemia. Exp Oncol. 42:78–79. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee SE, Choi SY, Kim SH, Song HY, Yoo HL,
Lee MY, Kang KH, Hwang HJ, Jang EJ and Kim DW: BCR-ABL1 transcripts
(MR4.5) at post-transplant 3 months as an early
predictor for long-term outcomes in chronic myeloid leukemia.
Korean J Intern Med. 32:125–136. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pai HL, Liu CY and Yeh MH:
Scleroderma-like lesions in a patient undergoing combined
pembrolizumab and routine chemotherapy: A case report and
literature review. Medicina (Kaunas). 60:10922024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang YN, Chu WY, Chen JS, Yeh YH and Cheng
CN: Long-term outcomes of chronic myeloid leukemia in children and
adolescents-real world data from a single-institute in Taiwan. J
Formos Med Assoc. S0929-6646(25)00014-2. 2025.(Epub ahead of
print). View Article : Google Scholar
|
|
26
|
Lang F, Wunderle L, Pfeifer H, Schnittger
S, Bug G and Ottmann OG: Dasatinib and azacitidine followed by
haploidentical stem cell transplant for chronic myeloid leukemia
with evolving myelodysplasia: A case report and review of treatment
options. Am J Case Rep. 18:1099–1109. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Leske IB and Hantschel O: The e13a3 (b2a3)
and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib.
Leukemia. 38:2041–2045. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hijiya N and Mauro MJ: Asciminib in the
treatment of philadelphia chromosome-positive chronic myeloid
leukemia: Focus on patient selection and outcomes. Cancer Manag
Res. 15:873–891. 2023. View Article : Google Scholar : PubMed/NCBI
|
